Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Codeine phosphate + pseudoephedrine hydrochloride + triprolidine is an oral small-molecule combination cough and cold product used for the temporary relief of cough and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. The combination contains **codeine phosphate**, an opioid antitussive that suppresses coughing primarily through central agonism at opioid receptors in the medullary cough center; **pseudoephedrine hydrochloride**, an indirect sympathomimetic decongestant that promotes norepinephrine release and reduces nasal congestion through adrenergic vasoconstrictive effects; and **triprolidine**, a first-generation H1 antihistamine that counters histamine-mediated allergic symptoms. It has been marketed under brand names including **Triacin-C** and **Pseudodine C**, typically as an oral syrup formulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on codeine phosphate + pseudoephedrine hydrochloride + triprolidine.